Have you considered Imugene (ASX:IMU)?
Fellow RAC shareholder
@johndprent and his sparring partner
@AlCp seem to have put in a lot of work over there recently. Though there seems to be some minor disagreement between them on the finer points. What I've gathered from a cursory read so far:
* Well funded
* Low SOI
* Top-notch management
* Low overheads
* Significant insider buying
* Multiple shots on goal
* Never released a bad announcement
* Developing a cure for cancer, aiming for 90% of the solid tumour market
* Potential catalysts include one or more "excellent" clinical trial updates anticipated in the near future
* Shares are currently being offered "cheap", so as to provide long term holders more upside (that's right isn't it
@AlCp?)
Apologies for any misrepresentations, errors or omissions in the above. DYOR.
(20min delay)